- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04316377
Norwegian Coronavirus Disease 2019 Study (NO COVID-19)
Norwegian Coronavirus Disease 2019 Study: An Open Labeled Randomized Controlled Pragmatic Trial to Evaluate the Antiviral Effect of Chloroquine in Adult Patients With SARS-CoV-2 Infection
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Chloroquine is one of two therapeutics (in addition to remdesivir) that has demonstrated in vitro inhibitory effects on SARS-CoV-2 and the drug is immediately available from national pharmacies. No delay is accordingly expected in treatment initiation after study commencement. In light of the evidence supporting chloroquine as a promising therapeutic in patients with COVID-19, the expected impact of the current proposal is considerable both in the short- and long-term. If successful, treatment with chloroquine has the potential to be the first evidence based treatment for COVID-19. The drug is affordable and the risk of side effects is low, making it an attractive therapeutic in large proportions of the population on a global scale.
In the current proposal aims to investigate the virological and clinical effects of chloroquine treatment in patients with established SARS-CoV-2 in need of hospital admission. The investigators hypothesize that early treatment with chloroquine in patients with established COVID-19 is safe and will significantly improve prognosis and impact clinical outcomes. More specifically, the investigators hypothesize that early treatment with chloroquine will increase the virological clearance rate of SARS-CoV-2, and lead to more rapid resolve of clinical symptoms, decreased proportion of patients with clinical deterioration and a decreased admission rate to intensive care units and in-hospital mortality. Considering the immediate and worldwide health emergency associated with the SARS-CoV-2 outbreak and the current lack of evidence based medical interventions for this patient group, studies investigating such possible treatment modalities in COVID-19 are direly needed.
The study is a two-arm, open label, pragmatic randomized controlled trial (RCT) designed to assess the virological and clinical effect of chloroquine therapy in patients with established COVID-19. Pragmatic clinical trials are characterized by focus on informing decision-makers on optimal clinical medicine practice and an intent to streamline procedures and data collection in the trial. By utilizing resources already paid for by the hospitals (physicians and nurses in daily clinical practice), pragmatic clinical trials can include a larger number of patients at a short time duration and at a lower cost. Due to the immediate need for study commencement and the time frame of the current proposal, a pragmatic approach will enable swift initiation of randomization and treatment. Data will be extracted from the data warehouse at Akershus University Hospital for eligible patient identification (i.e. electronic surveillance) and for automatic data extraction to the study specific database. The study will not be able to procure an acceptable placebo treatment and the study will accordingly not be placebo-controlled.
All patients at Akershus University Hospital with suspicion of acute respiratory tract infections are examined with a nasopharyngeal swab, with subsequent microbiological examination, including SARS-CoV-2 specific RT-PCR. Participants will be recruited from the entirety of the inpatients at the participating hospitals. Electronic real-time surveillance of laboratory reports from the Department of Microbiology will be examined regularly, with maximum interval 24 hours, for SARS-CoV-2 positive subjects.
The study aims to include patients by a sequential adaptive approach, where analyses are planned after the inclusion of 51 patients, with subsequent analyses after 101, 151 and 202 completed patients. All patients included in each sequence will be used for the final analyses of the entire study. This approach will enable frequent assessment of all outcome measures.
Data will be collected from the hospital electronic record system, including electronic patient records, laboratory and medical imaging systems, and prescribing systems. The data warehouse at Akershus University Hospital will be utilized for automatic data extraction to the study specific database. All clinical variables will be registered in the study eCRF system, including clinical endpoints and quantitative virological results from serial oropharyngeal specimens.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Lørenskog, Norway, 1478
- Akershus University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Hospitalised
- Adults 18 year or older
- Moderately severe disease (NEWS score ≤ 6)
- SARS-CoV-2 positive nasopharyngeal swab
- Expected time of admission > 48 hours
- Signed informed consent must be obtained and documented according to ICH GCP, and national/local regulations.
Exclusion Criteria:
- Requiring ICU admission at screening
- History of psoriasis
- Known adverse reaction to hydroxychloroquine sulphate
- Pregnancy
- Prolonged QT interval (>450 ms)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Treatment
Chloroquine therapy in addition to standard of care
|
400 mg hydroxychloroquine sulphate (equalling 310 mg base) twice daily for seven days
Other Names:
|
NO_INTERVENTION: No Treatment
Standard of care
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of decline in SARS-CoV-2 viral load
Time Frame: Baseline (at randomization) and at 96 hours
|
Viral load assessed by real time polymerase chain reaction in oropharyngeal samples
|
Baseline (at randomization) and at 96 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in National Early Warning Score score
Time Frame: Baseline (at randomization) and at 96 hours
|
National Early Warning Score score determines the degree of illness of a patient.
Scores range from 0-20, with a higher score representing further removal from normal physiology and a higher risk of morbidity and mortality.
|
Baseline (at randomization) and at 96 hours
|
Admission to intensive care unit
Time Frame: At all times after randomization during index admission (between admission and discharge, approximately 21 days)
|
Transfer from regular ward to intensive care unit during index admission
|
At all times after randomization during index admission (between admission and discharge, approximately 21 days)
|
In-hospital mortality
Time Frame: At all times after randomization during index admission (between admission and discharge, approximately 21 days)
|
All-cause mortality during index admission
|
At all times after randomization during index admission (between admission and discharge, approximately 21 days)
|
Duration of hospital admission
Time Frame: During index admission (between admission and discharge, approximately 21 days)
|
Total days admitted to the hospital (difference between admission date and discharge date of index admission)
|
During index admission (between admission and discharge, approximately 21 days)
|
Mortality at 30 and 90 days
Time Frame: At follow-up 30 and 90 days
|
All-cause mortality assessed at 30 and 90 days
|
At follow-up 30 and 90 days
|
Clinical status
Time Frame: 14 days after randomization
|
Percentage of subjects reporting each severity rating on a 7-point ordinal scale:
|
14 days after randomization
|
Change in C-reactive protein concentrations
Time Frame: Baseline (at randomization) and at 96 hours
|
Change in C-reactive protein concentrations from randomization to 96 hours after randomization
|
Baseline (at randomization) and at 96 hours
|
Change in alanine aminotransferase concentrations
Time Frame: Baseline (at randomization) and at 96 hours
|
Change in alanine aminotransferase concentrations from randomization to 96 hours after randomization
|
Baseline (at randomization) and at 96 hours
|
Change in aspartate aminotransferase concentrations
Time Frame: Baseline (at randomization) and at 96 hours
|
Change in aspartate aminotransferase concentrations from randomization to 96 hours after randomization
|
Baseline (at randomization) and at 96 hours
|
Change in bilirubin concentrations
Time Frame: Baseline (at randomization) and at 96 hours
|
Change in bilirubin concentrations from randomization to 96 hours after randomization
|
Baseline (at randomization) and at 96 hours
|
Change in estimated glomerular filtration rate
Time Frame: Baseline (at randomization) and at 96 hours
|
Change in estimated glomerular filtration rate from randomization to 96 hours after randomization
|
Baseline (at randomization) and at 96 hours
|
Change in cardiac troponin concentrations
Time Frame: Baseline (at randomization) and at 96 hours
|
Change in cardiac troponin concentrations from randomization to 96 hours after randomization
|
Baseline (at randomization) and at 96 hours
|
Change in natriuretic peptide concentrations
Time Frame: Baseline (at randomization) and at 96 hours
|
Change in natriuretic peptide concentrations from randomization to 96 hours after randomization
|
Baseline (at randomization) and at 96 hours
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Olav Dalgard, MD PhD, Akerhus University Hospital
Publications and helpful links
General Publications
- Lyngbakken MN, Berdal JE, Eskesen A, Kvale D, Olsen IC, Rueegg CS, Rangberg A, Jonassen CM, Omland T, Rosjo H, Dalgard O. A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics. Nat Commun. 2020 Oct 20;11(1):5284. doi: 10.1038/s41467-020-19056-6.
- Lyngbakken MN, Berdal JE, Eskesen A, Kvale D, Olsen IC, Rangberg A, Jonassen CM, Omland T, Rosjo H, Dalgard O. Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial. Trials. 2020 Jun 5;21(1):485. doi: 10.1186/s13063-020-04420-0.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- COVID-19
- Coronavirus Infections
- Infections
- Virus Diseases
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antirheumatic Agents
- Antiprotozoal Agents
- Antiparasitic Agents
- Antimalarials
- Hydroxychloroquine
Other Study ID Numbers
- REC 121446
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Corona Virus Infection
-
Ain Shams UniversityMisr International UniversityCompletedCorona Virus Infection | Corona Virus Disease 19 (Covid19) | Severe Acute Respiratory Syndrome Coronavirus 2(SARS-CoV2)Egypt
-
Montreal Heart InstituteNational Heart, Lung, and Blood Institute (NHLBI); Bill and Melinda Gates Foundation and other collaboratorsTerminatedCorona Virus InfectionSpain, United States, Canada, Brazil, Greece, South Africa
-
Fundación Instituto de Estudios de Ciencias de...Instituto de Investigación Biomédica de SalamancaTerminated
-
ANRS, Emerging Infectious DiseasesSciences Economiques et Sociales de la Santé & Traitement de l'Information... and other collaboratorsWithdrawn
-
National Institute of Allergy and Infectious Diseases...CompletedCorona Virus InfectionUnited States
-
The Cleveland ClinicCompletedCOVID | Corona Virus InfectionUnited States
-
NeurognosUnknownCOVID | Corona Virus Infection | SARS-CoV2Chile
-
University of Sao PauloMaria Aparecida de Andrade Moreira Machado; Thais Marchini de Oliveira ValarelliNot yet recruitingCorona Virus Infection | Exposure During Pregnancy
-
Chronic Obstructive Pulmonary Disease Trial Network...TerminatedVirus Diseases | Corona Virus Infection | Infection ViralDenmark
-
National Research Center for Cardiac Surgery, KazakhstanNazarbayev University Medical CenterRecruitingCovid19 | Corona Virus InfectionKazakhstan
Clinical Trials on Hydroxychloroquine Sulfate
-
Ravi Amaravadi, MDTerminatedCOVID-19United States
-
Health Institutes of TurkeyCompleted
-
Government of Punjab, Specialized Healthcare and...Harvard School of Public Health (HSPH); Forman Christian College, Pakistan; Services... and other collaboratorsTerminatedCOVID-19 | Coronavirus Infection | SARS-CoV-2 | Asymptomatic ConditionPakistan
-
SandozCompletedImmunosuppression | Rheumatism
-
Apsen Farmaceutica S.A.Federal University of São PauloWithdrawnCoronavirus Infections | SARS-CoV 2 | Pulmonary Disease | SARS (Severe Acute Respiratory Syndrome)Brazil
-
Rutgers, The State University of New JerseyTerminatedCOVID-19 | SARS-CoV-2United States
-
Government of Punjab, Specialized Healthcare and...Services Hospital, Lahore; Mayo Hospital Lahore; Pakistan Kidney and Liver InstituteTerminatedCovid-19 | Sars-CoV2 | Symptomatic ConditionPakistan
-
Patrick HensleyActive, not recruitingProstate Cancer RecurrentUnited States
-
Assistance Publique - Hôpitaux de ParisWithdrawn
-
Hackensack Meridian HealthCompletedCovid19United States